文献速递肾移植

ABO血型不相容肾移植结局的荟萃分析

ABO-Incompatible Kidney Transplant Outcomes: A Meta-Analysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-07-16

该荟萃分析纳入26项观察性研究,比较1346例ABO血型不相容与4943例ABO相容肾移植受者。ABO不相容组1年未删失移植物存活率为96%,低于相容组的98%,且抗体介导排斥、严重非病毒性感染和出血风险更高。

要点

  • ABO不相容肾移植1年移植物存活率96%,低于相容组的98%。
  • ABO不相容组抗体介导排斥、严重非病毒性感染和出血风险显著增加。
  • ABO不相容组报告的死因中感染占49%,显著高于相容组的13%。

核心结论

  • ABO血型不相容肾移植受者结局良好,但劣于中心匹配的ABO相容对照。

研究设计与样本

  • 在Embase、Medline、Cochrane、Web-of-Science和Google Scholar进行综合检索,最终纳入26项观察性研究,描述1346例ABO不相容患者和4943例ABO相容对照。

主要发现

  • ABO不相容组1年未删失移植物存活率为96%,ABO相容对照组为98%(相对风险0.97;95%置信区间0.96至0.98;P<0.001)。
  • ABO不相容组报告的死因中感染占49%,ABO相容组仅占13%(P=0.02)。
  • 抗体介导排斥(比值比3.86;95%置信区间2.05至7.29;P<0.001)、严重非病毒性感染(比值比1.44;95%置信区间1.13至1.82;P=0.003)和出血(比值比1.92;95%置信区间1.36至2.72;P<0.001)在ABO不相容移植后更常见。

临床怎么用

  • 临床应认识到ABO不相容肾移植虽总体结局良好,但需警惕感染、排斥和出血风险升高。

局限性

  • 研究为观察性研究荟萃分析,统计异质性低(移植物和患者存活I2为0%),偏倚风险低(所有研究≥7/9星)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: ABO blood group-incompatible kidney transplantation is considered a safe procedure, with noninferior outcomes in large cohort studies. Its contribution to living kidney transplantation programs is substantial and growing. Outcomes compared with center-matched ABO blood group-compatible control patients have not been ascertained. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Comprehensive searches were conducted in Embase, Medline, Cochrane, Web-of-Science, and Google Scholar. Meta-analyses Of Observational Studies in Epidemiology study guidelines for observational studies and Newcastle Ottawa bias scale were implemented to assess studies. Meta-analysis was performed using Review Manager 5.3. A subgroup analysis on antibody removal technique was performed. RESULTS: After identifying 2728 studies addressing ABO-incompatible kidney transplantation, 26 studies were included, describing 1346 unique patients who were ABO-incompatible and 4943 ABO-compatible controls. Risk of bias was low (all studies ≥7 of 9 stars). Baseline patient characteristics revealed no significant differences in immunologic risk parameters. Statistical heterogeneity of studies was low (I2 0% for graft and patient survival). One-year uncensored graft survival of patients who were ABO-incompatible was 96% versus 98% in ABO-compatible controls (relative risk, 0.97; 95% confidence interval, 0.96 to 0.98; P<0.001). Forty-nine percent of reported causes of death in patients who were ABO-incompatible were of infectious origin, versus only 13% in patients who were ABO-compatible (P=0.02). Antibody-mediated rejection (3.86; 95% confidence interval, 2.05 to 7.29; P<0.001), severe nonviral infection (1.44; 95% confidence interval, 1.13 to 1.82; P=0.003), and bleeding (1.92; 95% confidence interval, 1.36 to 2.72; P<0.001) were also more common after ABO-incompatible transplantation. CONCLUSIONS: ABO-incompatible kidney transplant recipients have good outcomes, albeit inferior to center-matched ABO-compatible control patients.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. de Weerd AE, Betjes MGH. ABO-Incompatible Kidney Transplant Outcomes: A Meta-Analysis. Clin J Am Soc Nephrol. 2018. PMID: 30012630. doi:10.2215/CJN.00540118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。